{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:57:47Z","timestamp":1790611067568,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K20505"],"award-info":[{"award-number":["25K20505"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ritsumeikan University","id":[{"id":"https:\/\/ror.org\/0197nmd03","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"DOI":"10.1007\/s40261-026-01591-7","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:27:19Z","timestamp":1790609239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare Cost Patterns in CDK4\/6 Inhibitor-Treated HR+\/HER2- Metastatic Breast Cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-611X","authenticated-orcid":false,"given":"Munenobu","family":"Kashiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1591_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1591_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055","author":"N Howlader","year":"2014","unstructured":"Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014. https:\/\/doi.org\/10.1093\/jnci\/dju055.","journal-title":"J Natl Cancer Inst"},{"key":"1591_CR3","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1607303.","journal-title":"N Engl J Med"},{"key":"1591_CR4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial. Lancet Oncol. 2018;19:904\u201315. https:\/\/doi.org\/10.1016\/S1470-2045(18)30292-4.","journal-title":"Lancet Oncol"},{"key":"1591_CR5","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"key":"1591_CR6","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"key":"1591_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andr\u00e9 F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"key":"1591_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"key":"1591_CR9","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1810527.","journal-title":"N Engl J Med"},{"key":"1591_CR10","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"key":"1591_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","volume":"381","author":"S-A Im","year":"2019","unstructured":"Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1903765.","journal-title":"N Engl J Med"},{"key":"1591_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im S-A, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1911149.","journal-title":"N Engl J Med"},{"key":"1591_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor\u2013positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial. JAMA Oncol. 2020;6:116\u201324. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4782.","journal-title":"JAMA Oncol"},{"key":"1591_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100332","volume":"6","author":"E Munzone","year":"2021","unstructured":"Munzone E, Pagan E, Bagnardi V, Montagna E, Cancello G, Dellapasqua S, et al. Systematic review and meta-analysis of post-progression outcomes in ER+\/HER2- metastatic breast cancer after CDK4\/6 inhibitors within randomized clinical trials. ESMO Open. 2021;6:100332. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100332.","journal-title":"ESMO Open"},{"key":"1591_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","volume":"365","author":"PM Rothwell","year":"2005","unstructured":"Rothwell PM. External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d Lancet. 2005;365:82\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(04)17670-8.","journal-title":"Lancet"},{"key":"1591_CR16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1080\/03007995.2024.2402074","volume":"40","author":"PP Masurkar","year":"2024","unstructured":"Masurkar PP, Prajapati P, Canedo J, Goswami S, Earl S, Bhattacharya K. Cost-effectiveness of CDK4\/6 inhibitors in HR+\/HER2- metastatic breast cancer: a systematic review and meta-analysis. Curr Med Res Opin. 2024;40:1753\u201367. https:\/\/doi.org\/10.1080\/03007995.2024.2402074.","journal-title":"Curr Med Res Opin"},{"key":"1591_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40261-024-01416-5","volume":"45","author":"A Pilehvari","year":"2025","unstructured":"Pilehvari A, You W, Kimmick G, Camacho F, Bonilla G, Anderson R. The cost-effectiveness of CDK4\/6 inhibitors in treating HR+\/HER2- metastatic breast cancer in the USA: When non-medication expenses are considered. Clin Drug Investig. 2025;45:59\u201368. https:\/\/doi.org\/10.1007\/s40261-024-01416-5.","journal-title":"Clin Drug Investig"},{"key":"1591_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1413676","volume":"14","author":"S Elazzazy","year":"2024","unstructured":"Elazzazy S, Al-Ziftawi NH, Mohamed Ibrahim MI, Bujassoum S, Hamad A. Comparative cost-effectiveness analysis of CDK4\/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov\u2019s model-based evaluation. Front Oncol. 2024;14:1413676. https:\/\/doi.org\/10.3389\/fonc.2024.1413676.","journal-title":"Front Oncol"},{"key":"1591_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","volume":"20","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20:1003\u20138. https:\/\/doi.org\/10.1016\/j.jval.2017.08.3019.","journal-title":"Value Health"},{"key":"1591_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence\u2014what is it and what can it tell us? N Engl J Med. 2016;375:2293\u20137. https:\/\/doi.org\/10.1056\/NEJMsb1609216.","journal-title":"N Engl J Med"},{"key":"1591_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1530391","volume":"15","author":"N Harbeck","year":"2025","unstructured":"Harbeck N, Brufsky A, Rose CG, Korytowsky B, Chen C, Tantakoun K, et al. Real-world effectiveness of CDK4\/6i in first-line treatment of HR+\/HER2- advanced\/metastatic breast cancer: updated systematic review. Front Oncol. 2025;15:1530391. https:\/\/doi.org\/10.3389\/fonc.2025.1530391.","journal-title":"Front Oncol"},{"key":"1591_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-022-06816-9","volume":"197","author":"M Kawai","year":"2023","unstructured":"Kawai M, Takada M, Nakayama T, Masuda N, Shiheido H, Cai Z, et al. Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database. Breast Cancer Res Treat. 2023;197:435\u201347. https:\/\/doi.org\/10.1007\/s10549-022-06816-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-025-07640-7","volume":"211","author":"T Kimura","year":"2025","unstructured":"Kimura T, Takami T, Piao Y, Wang M, Saji S. Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database. Breast Cancer Res Treat. 2025;211:233\u201344. https:\/\/doi.org\/10.1007\/s10549-025-07640-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s12282-025-01768-6","volume":"32","author":"T Nishina","year":"2025","unstructured":"Nishina T, Tanioka M, Takada K, Tsukioki T, Takahashi Y, Shien T, et al. Clinical significance on switching CDK4\/6 inhibitors among 13,284 patients with metastatic breast cancer. Breast Cancer (Auckl). 2025;32:1405\u201316. https:\/\/doi.org\/10.1007\/s12282-025-01768-6.","journal-title":"Breast Cancer (Auckl)"},{"key":"1591_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s10549-012-2097-2","volume":"134","author":"AJ Montero","year":"2012","unstructured":"Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a U.S. managed care perspective. Breast Cancer Res Treat. 2012;134:815\u201322. https:\/\/doi.org\/10.1007\/s10549-012-2097-2.","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.ctrv.2010.12.008","volume":"37","author":"TS Foster","year":"2011","unstructured":"Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW. The economic burden of metastatic breast cancer: a systematic review of literature from developed countries. Cancer Treat Rev. 2011;37:405\u201315. https:\/\/doi.org\/10.1016\/j.ctrv.2010.12.008.","journal-title":"Cancer Treat Rev"},{"key":"1591_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.18553\/jmcp.2018.24.6.514","volume":"24","author":"R Mistry","year":"2018","unstructured":"Mistry R, May JR, Suri G, Young K, Brixner D, Oderda G, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- advanced or metastatic breast cancer: a U.S. payer perspective. J Manag Care Spec Pharm. 2018;24:514\u201323. https:\/\/doi.org\/10.18553\/jmcp.2018.24.6.514.","journal-title":"J Manag Care Spec Pharm"},{"key":"1591_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10549-025-07720-8","volume":"212","author":"C Iwai","year":"2025","unstructured":"Iwai C, Miyawaki A, Konishi T, Okada A, Fujita A, Jo T, et al. Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis. Breast Cancer Res Treat. 2025;212:173\u201382. https:\/\/doi.org\/10.1007\/s10549-025-07720-8.","journal-title":"Breast Cancer Res Treat"},{"key":"1591_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s41999-024-01128-1","volume":"16","author":"K Komuro","year":"2025","unstructured":"Komuro K, Komuro J, Kaneko H, Suzuki Y, Okada A, Fujiu K, et al. The relationship between depression and cardiovascular disease in older people: results from a large-scale epidemiological cohort study in Japan. Eur Geriatr Med. 2025;16:673\u201380. https:\/\/doi.org\/10.1007\/s41999-024-01128-1.","journal-title":"Eur Geriatr Med"},{"key":"1591_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/hec.1653","volume":"20","author":"B Mihaylova","year":"2011","unstructured":"Mihaylova B, Briggs A, O\u2019Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897\u2013916. https:\/\/doi.org\/10.1002\/hec.1653.","journal-title":"Health Econ"},{"key":"1591_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492\u20139. https:\/\/doi.org\/10.1093\/aje\/kwm324.","journal-title":"Am J Epidemiol"},{"key":"1591_CR32","doi-asserted-by":"publisher","first-page":"e519","DOI":"10.1016\/j.clbc.2019.04.002","volume":"19","author":"J Giuliani","year":"2019","unstructured":"Giuliani J, Bonetti A. Palbociclib or ribociclib in first-line treatment in patients with hormone receptor-positive\/human epidermal receptor 2-negative advanced or metastatic breast cancer? A perspective based on pharmacologic costs. Clin Breast Cancer. 2019;19:e519\u201321. https:\/\/doi.org\/10.1016\/j.clbc.2019.04.002.","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"1591_CR33","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1177\/1078155220934531","volume":"26","author":"J Giuliani","year":"2020","unstructured":"Giuliani J, Bonetti A. The introduction of a third CDK4\/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR+)\/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020;26(6):1486\u201391. https:\/\/doi.org\/10.1177\/1078155220934531.","journal-title":"J Oncol Pharm Pract"},{"key":"1591_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00520-7","volume":"9","author":"A Grinshpun","year":"2023","unstructured":"Grinshpun A, Tolaney SM, Burstein HJ, Jeselsohn R, Mayer EL. The dilemma of selecting a first line CDK4\/6 inhibitor for hormone receptor-positive\/HER2-negative metastatic breast cancer. NPJ Breast Cancer. 2023;9:15. https:\/\/doi.org\/10.1038\/s41523-023-00520-7.","journal-title":"NPJ Breast Cancer"},{"key":"1591_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104103","volume":"10","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Layman RM, Lynce F, Liu X, Li B, McRoy L, et al. Comparative overall survival of CDK4\/6 inhibitors plus an aromatase inhibitor in HR+\/HER2- metastatic breast cancer in the US real-world setting. ESMO Open. 2025;10:104103. https:\/\/doi.org\/10.1016\/j.esmoop.2024.104103.","journal-title":"ESMO Open."},{"key":"1591_CR36","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1200\/JCO.22.02392","volume":"41","author":"K Kalinsky","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41:4004\u201313. https:\/\/doi.org\/10.1200\/JCO.22.02392.","journal-title":"J Clin Oncol"},{"key":"1591_CR37","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/JCO-24-02086","volume":"43","author":"K Kalinsky","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, et al. Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol. 2025;43:1101\u201312. https:\/\/doi.org\/10.1200\/JCO-24-02086.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1591_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","volume":"27","author":"R Mudumba","year":"2024","unstructured":"Mudumba R, Chan H-H, Cheng Y-Y, Wang C-C, Correia L, Ballreich J, et al. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States. Value Health. 2024;27(2):153\u201363. https:\/\/doi.org\/10.1016\/j.jval.2023.11.004.","journal-title":"Value Health"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01591-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:27:19Z","timestamp":1790609239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01591-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":38,"alternative-id":["1591"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01591-7","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"8 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used fully de-identified healthcare claims data from the DeSC-IQVIA Integrated Claims Database. In accordance with the Japanese Ethical Guidelines for Medical and Biological Research Involving Human Subjects (2021 revision), the dataset contained only anonymized information that could not be used to identify individual participants. Accordingly, ethics approval was not required under the applicable guidelines and institutional policies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data supporting the findings of this study are available from DeSC Healthcare, Inc. Restrictions apply to the availability of the data, which were used under a license for this study. Data are available from the authors upon reasonable request and with permission from DeSC Healthcare, Inc.","order":5,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The statistical analyses were performed using Python (version 3.8). The custom analysis code is not publicly available because it was developed for use with licensed claims data under a data use agreement and relies on database-specific variable definitions. Further information on the analytical code may be made available from the corresponding author upon reasonable request, subject to the terms of the data use agreement.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MK conceived and designed the study, performed the data analysis, and drafted the manuscript. KM supervised the study design and critically reviewed the manuscript. Both authors read and approved the final version of the manuscript and agree to be accountable for all aspects of the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}